Lupin launches its first brand medicine in Canada

April 20, 2015 06:41 pm | Updated 06:41 pm IST - Mumbai

The Canadian subsidiary of Mumbai-based pharmaceuticals firm Lupin Limited on Monday said it has launched its first brand product Zaxine in that country under a strategic licensing agreement.

The agreement with the North Carolina-based Salix Pharmaceuticals Inc grants Lupin Limited exclusive rights to promote, distribute and market the medicine in Canada.

Zaxine is a long-term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease under the cirrhosis category of disease.

As per the company, hepatic encephalopathy (HE) can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma.

“Lupin is in the process of establishing its Canadian presence and the launch opens up growth opportunities for the future,” the company said in a statement.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.